<p>Demographics of three children with newly diagnosed <i>ACVR1</i>-mutant DIPG treated with vandetanib and mTOR inhibitors upfront or at relapse</p>
<p>Summary of toxicities graded as per Common Terminology Criteria for Adverse Events version 4.03 related to vandetanib and/or mTOR inhibitors in three children with newl...
<p>Supplementary Figures S1-S3</p>
<p>Clinical experience of combined vandetanib and everolimus in a 7-year-old girl with ACVR1-mutant DIPG (case 1). <b>A,</b> Timeline summarizing the clinical ...
<p>Schema for AI-based identification of a repurposed drug combination strategy for <i>ACVR1</i>-mutant DIPG. The BenevolentAI knowledge graph was employed to ...
<p>Efficacy of combined vandetanib and everolimus <i>in vivo</i>. <b>A,</b> Tolerability in NOD.SCID mice exposed to daily oral treatment with the ...
<p>Synergy of combined vandetanib and everolimus <i>in vitro</i>. <b>A,</b> Cell viability matrix for <i>ACVR1</i><sup>R206H</...
<p>Validation of vandetanib as an ACVR1 inhibitor and everolimus as a P-gp inhibitor. <b>A,</b> Kinome selectivity map for vandetanib at 10 μmol/L, with red ci...
h-index: Number of publications with at least h citations each.